Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PTrana Meditama Metropolitan Tbk's quarterly Accounts Payable
declined
from Dec. 2025 (Rp217,897 Mil) to Mar. 2026 (Rp184,350 Mil) but then
increased
from Mar. 2026 (Rp184,350 Mil) to Jun. 2026 (Rp192,856 Mil).
PTrana Meditama Metropolitan Tbk's annual Accounts Payable
increased
from Dec. 2023 (Rp142,864 Mil) to Dec. 2024 (Rp177,139 Mil) and
increased
from Dec. 2024 (Rp177,139 Mil) to Dec. 2025 (Rp217,897 Mil).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.
What does a Accounts Payable of Rp192,856 Mil mean?
PTrana Meditama Metropolitan Tbk (ISX:SAME) has a Accounts Payable of Rp192,856 Mil as of Jun. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on PTrana Meditama Metropolitan Tbk and its competitors.
Is PTrana Meditama Metropolitan Tbk's Accounts Payable too high?
PTrana Meditama Metropolitan Tbk's current Accounts Payable is Rp192,856 Mil. Overall, PTrana Meditama Metropolitan Tbk has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does PTrana Meditama Metropolitan Tbk's Accounts Payable compare to HCA and THC?
PTrana Meditama Metropolitan Tbk's Accounts Payable of Rp192,856 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Healthcare Providers & Services company?
A good Accounts Payable depends on the Healthcare Providers & Services industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on PTrana Meditama Metropolitan Tbk and its competitors. PTrana Meditama Metropolitan Tbk's current Accounts Payable is Rp192,856 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PTrana Meditama Metropolitan Tbk stock overvalued right now?
Based on GuruFocus' analysis, PTrana Meditama Metropolitan Tbk (ISX:SAME) is currently considered Modestly Undervalued. The stock's GF Value™ is Rp354.65, compared to a current price of Rp320.00 — trading 9.8% below its estimated fair value. The current Accounts Payable is Rp192,856 Mil. PTrana Meditama Metropolitan Tbk's overall GF Score™ is 65/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For PTrana Meditama Metropolitan Tbk (ISX:SAME), the current Accounts Payable is Rp192,856 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PTrana Meditama Metropolitan Tbk (ISX:SAME) Overvalued in 2026?
Based on GuruFocus' analysis, PTrana Meditama Metropolitan Tbk stock appears to be undervalued.
The current stock price of Rp320.00 is trading 9.8% below its estimated GF Value™ of Rp354.65.
GuruFocus considers PTrana Meditama Metropolitan Tbk to be Modestly Undervalued.
Key valuation signals for ISX:SAME:
Accounts Payable: Rp192,856 Mil
GF Value™: Rp354.65 vs. price of Rp320.00 (9.8% below fair value)
No single metric tells the full story. See the ISX:SAME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Sarana Meditama Metropolitan Tbk is engaged in managing hospitals. Its hospitals are operated under the brand name Omni Hospital. The company manages and evaluates its business based on its geographic location consisting of Omni Pulomas, Omni Alam Sutera, Omni Cikarang, OMNI Pekayon, and others. It operates in Banten, DKI Jakarta, and West Java.
65GF Score
Get the complete analysis for ISX:SAME
Accounts Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:SAME has been successfully added to your 
